{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:29:29Z","timestamp":1792726169294,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semradonc.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:14:58Z","timestamp":1741936498000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["De-escalated Management of HPV-positive Oropharyngeal Carcinoma: Improving Outcomes with Personalized Approaches"],"prefix":"10.1016","volume":"35","author":[{"given":"Irini","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Safavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semradonc.2025.01.004_bib0001","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/jso.26687","article-title":"Epidemiology and incidence of HPV-related cancers of the head and neck","volume":"124","author":"Roman","year":"2021","journal-title":"J Surg Oncol"},{"issue":"32","key":"10.1016\/j.semradonc.2025.01.004_bib0002","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.01.004_bib0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1473-3099(18)30802-8","article-title":"Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness","volume":"19","author":"Lechner","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000375148","article-title":"The fidelity of p16 staining as a surrogate marker of Human papillomavirus status in fine-needle aspirates and core biopsies of neck node metastases: Implications for HPV testing protocols","volume":"59","author":"Holmes","year":"2015","journal-title":"Acta Cytol"},{"issue":"40","key":"10.1016\/j.semradonc.2025.01.004_bib0007","doi-asserted-by":"crossref","first-page":"16175","DOI":"10.1073\/pnas.1310432110","article-title":"Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines","volume":"110","author":"McLaughlin-Drubin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.semradonc.2025.01.004_bib0008","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0002-9440(10)63871-0","article-title":"Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus","volume":"162","author":"Klussmann","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0009","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.oraloncology.2018.01.010","article-title":"Double positivity for HPV-DNA\/p16(ink4a) is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients","volume":"78","author":"Mena","year":"2018","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2012.03.033","article-title":"HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer - How valid is p16INK4A as surrogate marker?","volume":"323","author":"Hoffmann","year":"2012","journal-title":"Cancer Lett"},{"issue":"10166","key":"10.1016\/j.semradonc.2025.01.004_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(15)00560-4","article-title":"Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): A multicentre cohort study","volume":"17","author":"O'Sullivan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8020826","article-title":"Prognostic significance of a scoring system combining p16, smoking, and drinking status in a series of 131 patients with oropharyngeal cancers","volume":"2021","author":"Bouland","year":"2021","journal-title":"Int J Otolaryngol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.01.004_bib0014","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/healthcare11060906","article-title":"Serious long-term effects of head and neck cancer from the survivors\u2019 point of view","volume":"11","author":"Taylor","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.semradonc.2025.01.004_bib0015","first-page":"E2151","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.semradonc.2025.01.004_bib0016","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1743-7563.2011.01405.x","article-title":"Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients","volume":"7","author":"Otty","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"issue":"21","key":"10.1016\/j.semradonc.2025.01.004_bib0017","first-page":"6","article-title":"Weekly versus three-Weekly cisplatin-based concurrent chemoradiotherapy as definitive treatment in Head and Neck cancer- where do we stand?","volume":"1","author":"Rawat","year":"2016","journal-title":"Gulf J Oncolog"},{"issue":"11","key":"10.1016\/j.semradonc.2025.01.004_bib0018","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: A phase III randomized noninferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.semradonc.2025.01.004_bib0019","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): A multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.semradonc.2025.01.004_bib0020","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10166","key":"10.1016\/j.semradonc.2025.01.004_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with Cisplatin versus Cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0023","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - A Trans-Tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.semradonc.2025.01.004_bib0024","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.01.004_bib0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005: A randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2025.01.004_bib0026","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/COC.0000000000000064","article-title":"Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes","volume":"38","author":"Tam","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.oraloncology.2016.04.011","article-title":"Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT","volume":"58","author":"Gutiontov","year":"2016","journal-title":"Oral Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.prro.2016.11.002","article-title":"Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy","volume":"7","author":"Leeman","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0030","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2012.08.004","article-title":"Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy","volume":"85","author":"Garden","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2025.01.004_bib0031","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.ijrobp.2009.04.006","article-title":"Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: Clinical outcomes and patterns of failure","volume":"76","author":"Daly","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0032","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.radonc.2020.01.005","article-title":"Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome","volume":"143","author":"Deschuymer","year":"2020","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.01.004_bib0033","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2020.09.063","article-title":"Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer","volume":"109","author":"Sher","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.01.004_bib0034","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jamaoncol.2021.6416","article-title":"Evaluation of substantial reduction in elective radiotherapy dose and field in patients with Human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy","volume":"8","author":"Tsai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.semradonc.2025.01.004_bib0035","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ijrobp.2009.06.090","article-title":"Radiotherapy dose-volume effects on salivary gland function","volume":"76","author":"Deasy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0036","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-4-52","article-title":"Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy","volume":"4","author":"Li","year":"2009","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.01.004_bib0037","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.01.004_bib0038","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.01.004_bib0039","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.01.004_bib0040","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant Nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.01.004_bib0041","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","article-title":"Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial","volume":"95","author":"Misiukiewicz","year":"2019","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.01.004_bib0042","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.semradonc.2025.01.004_bib0043","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0360-3016(97)00101-6","article-title":"Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck","volume":"38","author":"Brizel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0044","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","article-title":"Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study","volume":"77","author":"Nordsmark","year":"2005","journal-title":"Radiother Oncol"},{"issue":"23","key":"10.1016\/j.semradonc.2025.01.004_bib0045","first-page":"7066","article-title":"Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer","volume":"62","author":"Kaanders","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2025.01.004_bib0046","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients","volume":"36","author":"Rasey","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1016\/j.semradonc.2025.01.004_bib0047","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","volume":"24","author":"Rischin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","article-title":"Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced Human papillomavirus-related oropharyngeal carcinoma","volume":"96","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2025.01.004_bib0049","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djaa184","article-title":"Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial","volume":"113","author":"Riaz","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.semradonc.2025.01.004_bib0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of Human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.01.004_bib0051","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijrobp.2023.03.043","article-title":"Initial feasibility and acute toxicity outcomes from a phase 2 trial of (18)F-fluorodeoxyglucose positron emission tomography response-based de-escalated definitive chemoradiotherapy for p16+ oropharynx cancer: A planned interim analysis","volume":"117","author":"Allen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2025.01.004_bib0052","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2025.01.004_bib0053","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:54:06Z","timestamp":1741938846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1053429625000049"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.01.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalated Management of HPV-positive Oropharyngeal Carcinoma: Improving Outcomes with Personalized Approaches","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}